drugset / Trial / NCT04506983
GPC3-CAR-T Cells for the Hepatocellular Carcinoma
Phase 1
Suspended
12 enrolled
Beijing Tsinghua Chang Gung Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of GPC3-CAR-T cells in patients with hepatocellular carcinoma.
Timeline
- Start
- 2022-06-10
- Primary completion
- 2023-06-10
- Completion
- 2023-10-10
Outcome
Outcome not reported
Stopped: “Adjust the plan”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GPC3-CART cells | Cell therapy | 1e+06 cells | Intravenous |
| Subject | GPC3-CART cells | Cell therapy | 3e+06 cells | Intravenous |
| Subject | GPC3-CART cells | Cell therapy | 1e+07 cells | Intravenous |